Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376730 | 1.00 | RIPK1 (0.47) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL2079847 | 1.00 | RIPK1 (0.47) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL10526965 | 0.83 | RIPK1 (0.49) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL17864360 | 0.82 | PRKACA (0.49) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL10211441 | 0.81 | RIPK1 (0.47) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL10211434 | 0.81 | RIPK1 (0.47) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL11744344 | 0.79 | SLC6A2 (0.50) | TRPA1KDM4EL3MBTL1CYP2D6SLC6A2 | |
| SCHEMBL1520851 | 0.79 | LMNA (0.52) | RIPK1EPHX2KDM4E | |
| SCHEMBL18539292 | 0.79 | AOC3 (0.52) | RIPK1ROCK2ROCK1MAPK13RPS6KA5 | |
| SCHEMBL16323165 | 0.79 | LMNA (0.52) | RIPK1EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465590-B2 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-11-11 | — | — | US | disclosed |
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| CN-118541348-A | 4-Substituted-phenylacetamides and aryl ureas as agonists of the orphan receptor GPR88 | 研究三角协会 | 2024-08-23 | — | — | CN | disclosed |
| CN-113272309-B | Tricyclic inhibitors of hepatitis b virus | 圣拉斐尔医院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | Antios Therapeutics, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220241241-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) | 2022-08-04 | — | — | US | disclosed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | disclosed |
| EP-3825318-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020234483-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) | 2020-11-26 | — | — | WO | disclosed |
| US-7351833-B2 | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBOTT LABORATORIES (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080070891-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080004448-A1 | (1S,5S)-3-(5.6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBVIE INC. | 2008-01-03 | — | — | US | disclosed |
| CN-101035789-A | (1S,5S) -3- (5, 6-dichloro-3-pyridinyl) -3, 6-diazabicyclo [3.2.0] heptane | ABBOTT LAB (US) | 2007-09-12 | — | — | CN | disclosed |
| EP-1778692-A2 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBOTT LABORATORIES (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1771451-A2 | (1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBOTT LABORATORIES (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006019668-A2 | (1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBOTT LABORATORIES (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006019660-A2 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBOTT LABORATORIES (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035936-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465590-B2 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | OAT, SLC10A1, OTC | RIPK1 1435/4885ROCK2 4084/4885ROCK1 3675/4885 |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | DHPS, HCN2, DCPS | RIPK1 4413/4885ROCK2 4417/4885ROCK1 4416/4885 |
| US-20080004448-A1 | (1S,5S)-3-(5.6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | DHPS, HCN2, DCPS | RIPK1 4411/4885ROCK2 4428/4885ROCK1 4427/4885 |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | HAVCR2, NR1H4, HCCS | RIPK1 1646/4885ROCK2 2359/4885ROCK1 2308/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | RIPK1 1646/4885ROCK2 2359/4885ROCK1 2308/4885 |
| US-20080070891-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | CHRNA6, CHRNA5, CHRNA3 | RIPK1 4034/4885ROCK2 3474/4885ROCK1 3243/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | RIPK1 1672/4885ROCK2 1347/4885ROCK1 1248/4885 |
| US-20220241241-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OAT, OTC, SLC10A1 | RIPK1 947/4885ROCK2 3825/4885ROCK1 3820/4885 |
| US-20060035936-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | CHRNA6, CHRNA5, CHRNA3 | RIPK1 4034/4885ROCK2 3474/4885ROCK1 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.